Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Senior Appointment

30 Jan 2008 07:01

ViaLogy PLC30 January 2008 VIALOGY PLC APPOINTS HEAD OF OPERATIONS AND ENGINEERING London, January 30, 2008 - ViaLogy PLC (AIM: VIY), a leading innovator ofnetwork-centric real time signal processing platforms for integrated security,safety, operations management and business continuity applications, todayannounces the appointment of Hugo Fruehauf as Chief Operating Officer (COO) andVice President of Engineering at its wholly-owned American subsidiary company,ViaLogy LLC ('ViaLogy'), of Pasadena, California. This senior appointment strengthens the company's engineering and productioncapabilities and advances efforts to establish its unique product offerings -Sensor Policy Manager (SPM), MicroSPM and MPEX Electronic Eye - in high demandcommercial markets. Fruehauf joins ViaLogy from Frequency Electronics Inc. (FEI), a leadingmanufacturer of precision frequency sources and frequency/time systems forsatellites, missiles, aircraft and a host of ground platforms, where he was VicePresident and Chief Technology Officer (CTO). Hugo has also held President/CEOand CTO positions at subsidiaries of FEI, the Defense Group of AlliantTechsystems, Datum Inc., and Ball-Efratom (a Ball Aerospace company); companiesserving both commercial and military/governmental system markets. Prior tothese roles, while at Rockwell International, he was the Chief Engineer for thedesign and development of the satellite for the now famous GPS GlobalPositioning System. He also played a leading role in the Apollo moon landingprogram, as Chief Test Conductor and Complex Operations Manager for the secondstage of the Saturn V launch vehicle. Mr. Fruehauf is considered a leading expert in GPS navigation, positioning andprecision timing for commercial and military applications, as well as precisionfrequency sources and network cryptographic security technologies. He is also anAdjunct Professor at Pepperdine University. Commenting on his appointment Hugo Fruehauf said: "I'm looking forward to leading an incredibly competent team at the Pasadenafacility and hopefully contribute to innovation, a systems engineering focus,and the operational glue that will bring ViaLogy to its full potential." Welcoming Hugo to ViaLogy, Dr. Robert W. Dean, President/CEO, said: "We are delighted that Hugo is joining the team at ViaLogy. He brings a wealthof experience in product design and development that will be vital as weroll-out our products to the market. We are all looking forward to an excitingyear ahead." Mr. Fruehauf is a Registered Professional Engineer in Control Systems (State ofCalifornia); an Executive MBA graduate (Pepperdine University); an ElectronicEngineering Technology graduate (DeVry University); the compiler of a "PrecisionTime and Frequency Handbook" and a religious book "God Without Dogma"; author ofmany technical papers on atomic oscillators, telecommunications, networkcryptography, and GPS technologies; holds numerous patents; and received awardsfor his role in the Apollo program, GPS, and an IEEE technical paper. ViaLogyRobert W Dean, President/CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 Nominated Advisor (Seymour Pierce)Mark Percy +44 (0) 20-7107-8000 PR Consultants - Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0) 20-7822-0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications and sensor fusion. ViaLogy is currentlydeploying and designing computational systems, powered by its patentedtechnologies, for applications in life sciences, public safety and security,surveillance, defense and geoseismology. Vialogy focuses on market drivenproblems where automation, timeliness, quality and reliability of informationprocessing are essential. ViaLogy's core competency incorporates rapidly andaccurately detecting weak signals buried in high noise background and clutter.This technology can be employed to solve problems involving sensor integrationand information overload challenges involving video, telephony and controlsensors, as well as for enhancement of numerous signal processing applications.For more information, visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.